552
Views
35
CrossRef citations to date
0
Altmetric
Articles

Disposition, Oral Bioavailability, and Tissue Distribution of Zearalenone in Rats at Various Dose Levels

, , , , , , , , , & show all
Pages 1406-1411 | Published online: 29 Dec 2009
 

Abstract

This study was conducted to characterize the disposition, oral bioavailability, and tissue distribution of zearalenone in rats. The pharmacokinetics and tissue distribution of zearalenone were studied after intravenous (iv) or oral (po) administration at doses ranging from 1 to 8 mg/kg in intact and bile duct-cannulated rats. Serum, bile, and urine concentrations were determined by liquid chromatography and mass spectroscopy (LC/MS/MS) and tissue concentrations by high-performance liquid chromatography (HPLC)/fluorescence detection assays. Noncompartmental methods were used for pharmacokinetic analysis. Average Cls (range 5.0–6.6 L/h/kg) and Vdss (range 2–4.7 L/kg) remained unaltered over an iv dose range from 1 to 8 mg/kg, and area under the concentration–time curve (AUC) and initial peak concentrations increased linearly with dose. Minimal quantities of zearalenone were excreted unchanged in urine (fe,urine 0.5 ± 0.2%) and bile (fe,bile 0.91 ± 0.64%). After po administration of 8 mg/kg, zearalenone was rapidly absorbed and serum concentration–time profiles showed a distinct second peak. The absolute oral bioavailability was low (2.7%). Comparing bile duct-cannulated to intact rats at a dose of 8 mg/kg, the impact of biliary excretion on overall pharmacokinetics was more pronounced after po than after iv administration. Upon iv infusion to steady state, the highest zearalenone concentration was found in small intestine, followed by kidneys, liver, adipose tissue, and lung. Zearalenone concentrations in stomach, heart, brain, spleen, muscle, and testes were lower than those found in serum. The pharmacokinetics and tissue distribution data from this study may be useful to develop physiologically based pharmacokinetic (PBPK) models for zearalenone and subsequently to predict the pharmacokinetics and toxicity in humans.

This work was supported by the Korea Food and Drug Administration, grant 08182–488.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.